A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression

Cancer Categories

Karmanos Trial ID

NCT ID

Age Group

Scope

Phase

Principal Investigator

Primary Objectives:

To compare OS between ivonescimab versus pembrolizumab
To compare PFS assessed by the Independent Radiology Review Committee (IRRC) based on RECIST v1.1 between ivonescimab and pembrolizumab

Secondary Objectives:

To compare the ORR, DCR, and DoR between ivonescimab versus pembrolizumab, as assessed by the IRRC, based on RECIST v1.1
To evaluate the safety and tolerability of ivonescimab and compare to pembrolizumab
To evaluate the PK profile of ivonescimab
To evaluate the immunogenicity of ivonescimab

Eligibility

Inclusion Criteria:

Age ≥ 18 years old at the time of enrollment
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1
Expected life expectancy ≥ 3 months
Metastatic (Stage IV) NSCLC
Histologically or cytologically confirmed squamous or non-squamous NSCLC
Tumor demonstrates high PD-L1 expression ( TPS>50%) based on a 22C3 immunohistochemistry ( IHC) clinical assay approved / cleared by local health authorities.
At least one measurable noncerebral lesion according to RECIST 1.1
No prior systemic treatment for metastatic NSCLC.

Exclusion Criteria:

Histologic or cytopathologic evidence of the presence of small cell lung carcinoma for which first-line approved therapies are indicated. For patients with non-squamous histology, actionable driver mutation testing results are required before randomization.
Has received any prior therapy for NSCLC in the metastatic setting.
Concurrent enrollment in another clinical study, unless patient is enrolled in a non-interventional clinical study or is completing survival follow -up.
Known actionable genomic alterations for which first-line approved therapies are indicated
Symptomatic CNS metastases, CNS metastasis ≥ 1.5 cm, CNS radiation within 7 days prior to randomization, potential need for CNS radiation within the first cycle, or leptomeningeal disease
Other prior malignancy (including previously treated NSCLC) unless the patient has undergone curative therapy with no evidence of recurrence of the disease for 3 years prior to randomization
Active autoimmune or lung disease requiring systemic therapy
Has pre-existing peripheral neuropathy that is ≥ Grade 2 by CTCAE version 5
Severe infection within 4 weeks prior to randomization
Major surgical procedures or serious trauma within 4 weeks prior to randomization

Locations

4100 John R
Detroit, MI 48201
Get Directions

Phone: 1-800-527-6266

3520 Forest Rd.
Lansing, MI 48910
Get Directions

Phone: 517-975-9500

31995 Northwestern Hwy
Farmington Hills, MI 48334
Get Directions

Phone: 1-800-527-6266

Applicable Disease Site

Therapies, Drugs, Devices